Bibliografia UJ CM

1/45
S[zczepan] Jakubowski, P[aweł] Kawalec, P[rzemysław] Holko.
CEE: Brief Overview of Orphan Drug Reimbursement and Selected Clinical Characteristics
Value in Health
2022 : Vol. 25, nr 12 Suppl., s. S254, abstr. HPR123
ISPOR Europe 2022 Abstracts
p-ISSN: 1098-3015
SZZ
SIF
Adres url:
2/45
S[zczepan] Jakubowski, P[aweł] Kawalec, K. Malinowski.
Relationship/Association between Clinical Potential of Orphan Drugs and Registration Status Assigned By the European Medicines Agency : Selected Aspects
Value in Health
2022 : Vol. 25, nr 7 Suppl., s. S469, abstr. HPR14
The Future of HEOR in Patient-Driven Digital Healthcare Systems
p-ISSN: 1098-3015
SZZ
SIF
Adres url:
3/45
J. Roth, M. Dobek, M. Galazka-Sobotka, I[wona] Kowalska-Bobko, E. Makomaska-Szaroszyk, M. Niewada, T. Macioch.
Hospital-Based Health Technology Assessments in Europe And North America Systematic Review.
Value in Health
2019 : Vol. 22, Suppl. 3, s. S803-S804, abstr. PNS249.
ISPOR Europe, Copenhagen, Denmark, 2019.
p-ISSN: 1098-3015
SZZ
SIF
4/45
P[aweł] Kawalec, E. Stawowczyk.
A physician based assessment of disease activity, quality of life and costs of ulcerative colitis in Poland.
Value in Health
2017 : Vol. 20, nr 5, s. A219, abstr. PSY58.
p-ISSN: 1098-3015
SZZ
SIF
5/45
P. Holko, P[aweł] Kawalec, E. Stawowczyk.
Direct costs of inflammatory bowel diseases therapy in Poland - nationwide database analysis.
Value in Health
2017 : Vol. 20, nr 9, s. A553, abstr. PSY52.
ISPOR 20th Annual European Congress, Glasgow, UK, November 2017.
p-ISSN: 1098-3015
SZZ
SIF
Adres url:
6/45
K. Skora, T[omasz] Bochenek, J. Augustynska, J. Walczak.
Economic Evaluation and Cost-Effectiveness Threshold in Practice of Decision-Making on Orphan Drug Reimbursement in Poland.
Value in Health
2017 : Vol. 20, nr 9, s. A563-A564, abstr. PSY109.
ISPOR 20th Annual European Congress, Glasgow, UK, November 2017.
p-ISSN: 1098-3015
SZZ
SIF
Adres url:
7/45
P[aweł] Kawalec, K. Malinowski, E. Stawowczyk.
Relation between Polish HTA recommendations and reimbursement decisions.
Value in Health
2017 : Vol. 20, nr 5, s. A44, abstr. PHP163.
p-ISSN: 1098-3015
SZZ
SIF
8/45
P[aweł] Kawalec, K. Malinowski.
Relation of Polish HTA recommendations and decisions issued by selected national HAT agencies.
Value in Health
2017 : Vol. 20, nr 5, s. A44, abstr. PHP164.
p-ISSN: 1098-3015
SZZ
SIF
9/45
K. Skora, T[omasz] Bochenek, J. Augustynska, J. Walczak.
The Practice of Decision-Making of Public Health Authorities In Poland on Reimbursement of Orphan Drugs.
Value in Health
2017 : Vol. 20, nr 9, s. A564, abstr. PSY111.
ISPOR 20th Annual European Congress, Glasgow, UK, November 2017.
p-ISSN: 1098-3015
SZZ
SIF
Adres url:
10/45
D. Kuliś, A. Bottomley, C. Whittaker, L.V. van de Poll-Franse, A. Darlington, B. Holzner, M. Koller, J.C. Reijneveld, K[rzysztof] A[ndrzej] Tomaszewski, M. Gronvold.
The Use of the EORTC Item Library to Supplement EORTC Quality of Life Instruments.
Value in Health
2017 : Vol. 20, nr 9, s. A775, abstr.
ISPOR 20th Annual European Congress, Glasgow, UK, November 2017.
p-ISSN: 1098-3015
SZZ
SIF
11/45
P[aweł] Kawalec.
Disease Activity, Quality of Life and Indirect Costs Associated with Ulcerative Colitis in Poland.
Value in Health
2016 : Vol. 19, nr 7, s. A585, abstr. PSY60.
ISPOR 19th Annual European Congress Research Abstracts, Vienna, Austria, October 29-November 2, 2016, ISPOR 7th Asia-Pacific Conference Abstracts, Singapore, September 3-6, 2016.
p-ISSN: 1098-3015
SZZ
SIF
12/45
T[omasz] Bochenek, E[wa] Kocot, M. Rodzinka, B. Godman, K. Maciejewska, S. Kamal, A[ndrzej] Pilc.
The Transparency of Published Recommendations on Reimbursement of Health Technologies in Poland.
Value in Health
2016 : Vol. 19, nr 7, s. A447, abstr. PHP48.
ISPOR 19th Annual European Congress Research Abstracts, Vienna, Austria, October 29-November 2, 2016, ISPOR 7th Asia-Pacific Conference Abstracts, Singapore, September 3-6, 2016.
p-ISSN: 1098-3015
SZZ
SIF
13/45
P[aweł] Kawalec, P. Holko, J. Lis, M. Glasek.
Cost-utility analysis and cost-minimisation analysis of SabrilŽ (Vigabatrin) in drug-resistant epilepsy from payer's perspective in Poland.
Value in Health
2012 : Vol. 15, nr 7, s. A553
ISPOR 15th Annual European Congress, Berlin, Germany, November 3-7, 2012.
SZZ
SIF
14/45
P[aweł] Kawalec, P. Holko, M. Boratynska, M. Glyda, E[wa] Ignacak, M. Russel-Szymczyk, M. Szkultecka-Sebek, A. Kaweczynska-Lason.
Cost-effectiveness and cost-utility analysis of 200 days prophylaxis of cytomegalovirus (CMV) infections in high risk (D+/R-) kidney transplant recipients in Poland.
Value in Health
2011 : Vol. 14, nr 7, s. A280-A281
ISPOR 14th Annual European Congress, Madrid, Spain, November 5-8, 2011.
SZZ
SIF
15/45
P[aweł] Kawalec, P. Badurak, T. Denisso, D. Jastrzebski, M. Marek, A. Pluzanski, A. Szczesna, M. Szkultecka-Debek, M. Russel-Szymczyk.
Bevacizumab + paclitaxel + carboplatin (Bev + Pac + Car) vs. pemetrexed + cisplatin (Pem + Cis) in adenocarcinoma non-squamous non-small Cell Lung Cancer (NSCLC): a cost-effectiveness analysis from a Polish public payer's perspective.
Value in Health
2010 : Vol. 13, nr 7, s. A268
ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010.
SZZ
SIF
16/45
R. Oleszko, P[aweł] Kawalec, A. Drobniak, R. Stec, J[oanna] Streb, M. Russel-Szymczyk, M. Szkultecka-Debek.
Budget impact analysis of capecitabine in adjuvant treatment of patients with resected Dukes' c colon cancer (cc) from Polish public payer's and patient's perspectives.
Value in Health
2010 : Vol. 13, nr 7, s. A257
ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010.
SZZ
SIF
17/45
P[aweł] Kawalec, M. Czech.
Cost of diabetes mellitus type 1 and 2 studies in countries of central and eastern Europe-a systematic review of the litarature.
Value in Health
2010 : Vol. 13, nr 7, s. A288-A289
ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010.
SZZ
SIF
18/45
P[aweł] Kawalec, P. Holko, A. Krzyzanowska, C. Glogowski.
The budget impact analysis of ambrisentan in 2nd line treatment of adult patients with idiopathic, familiar or associated with connective tissue disease pulmonary hypertension of III NYHA stage.
Value in Health
2010 : Vol. 13, nr 7, s. A347
ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010.
SZZ
SIF
19/45
P[aweł] Kawalec, E. Stawowczyk, M. Russel-Szymczyk, M. Szkultecka-Debek, R. Aultman, E. Carr, E[wa] Lech-Maranda, A. Krawcewicz, M. Wach, G. Mazur.
An economic evaluation of rituximab versus other first-line treatments for patients with Chronic Lymphocytic Leukemia in Poland.
Value in Health
2009 : Vol. 12, nr 7, s. A273, abstr. PCN88
ISPOR Twelfth Annual European Congress, Paris, France, October 24-27, 2009.
SZZ
SIF
20/45
P[aweł] Kawalec, J. Gierczynski, J. Lis, M. Glasek.
Budget impact analysis of reimbursement of aravaŽ (leflunomide) in the treatment of rheumatoid arthritis in Poland.
Value in Health
2009 : Vol. 12, nr 7, s. A436
ISPOR Twelfth Annual European Congress, Paris, France, October 24-27, 2009.
SZZ
SIF
21/45
P[aweł] Kawalec, J[acek] Kuzma, C. Glogowski, A. Krzyzanowska.
Cost-effectiveness of fondaparinux vs enoxaparin in extended prophylaxis of venous thromboembolism in major orthopedic surgery in Poland.
Value in Health
2009 : Vol. 12, nr 7, s. A334
ISPOR Twelfth Annual European Congress, Paris, France, October 24-27, 2009.
SZZ
SIF
22/45
P[aweł] Kawalec, J[acek] Kuzma, M. Szkultecka-Debek, M. Russel-Szymczyk, A. Slizien-Debska, J. Malyszko, M. Durlik.
Cost-minimization analysis: Mircera (methoxy polyethylene glycol-epoetin beta) vs. Aranesp (darbepoetin alfa) in patients with chronic kidney disease (ckd) who are not receiving haemodialysis, in Polish setting.
Value in Health
2009 : Vol. 12, nr 7, s. A310
ISPOR Twelfth Annual European Congress, Paris, France, October 24-27, 2009.
SZZ
SIF
23/45
P[aweł] Kawalec, P. Holko, D. Dziurda, C. Glogowski.
Economic assessment of mass vaccination with pneumococcal non-typeable haemophilus influenzae protein d conjugate vaccine (phid-cv) in Poland.
Value in Health
2009 : Vol. 12, nr 7, s. A423
ISPOR Twelfth Annual European Congress, Paris, France, October 24-27, 2009.
SZZ
SIF
24/45
P[aweł] Kawalec, A. Szawlowski, I. Federowicz, M[onika] Szkultecka-Debek, M. Russel-Szymczyk.
Cost minimization analysis of advanced gastric cancer treatment with capecitabine/cispatine (XP) vs. 5-FU/cispatin (FP) regiments.
Value in Health
2008 : Vol. 11, nr 6, s. A473, abstr. PCN44
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
25/45
J[acek] Kuzma, P[aweł] Kawalec, P. Bochenski.
Cost-effectiveness analysis of drotrecogin alfa (Activated; DAA) as a treatment for severe sepsis with multiple organ failure (MOF) in Poland.
Value in Health
2008 : Vol. 11, nr 6, s. A438, abstr. PIN30
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
26/45
P[aweł] Kawalec, J. Lis, M. Glasek.
Cost-effectiveness and cost-utility analysis of Tritace Comb (Ramipril/HCTZ) in treatment of hypertension in Poland.
Value in Health
2008 : Vol. 11, nr 6, s. A391-A392, abstr. PCV36
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
27/45
P. McEwan, A. Woehl, P[aweł] Kawalec, J. Lis, J. Gierczynski, J. Walczak.
Cost-utility of insulin glargine compared to NPH in type DMI from a public payer perspective in Poland.
Value in Health
2008 : Vol. 11, nr 6, s. A508, abstr. PDB40
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
28/45
P. McEwan, A. Woehl, P[aweł] Kawalec, J. Lis, J. Gierczynski, J. Walczak.
Cost-utility of insulin glargine compared to premix in type 2 from public payer perspective in Poland.
Value in Health
2008 : Vol. 11, nr 6, s. A509, abstr. PDB42
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
29/45
P. McEwan, A. Woehl, P[aweł] Kawalec, J. Lis, J. Gierczynski, J. Walczak.
Is insulin glargine a cost-effective option for treatment of patients naive to insulin treatment with type 2, baseline HBA 1C above 8% and age below 65 years in comparison to NPH and premix in Poland.
Value in Health
2008 : Vol. 11, nr 6, s. A507, abstr. PDB37
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
30/45
P. McEwan, A. Woehl, P[aweł] Kawalec, J. Lis, J. Gierczynski, J. Walczak.
Is insulin glargine a cost-effective option in treatment of patients with DMI with baseline HBAC above 8% in comparison to NPH and premix in Poland?
Value in Health
2008 : Vol. 11, nr 6, s. A508, abstr. PDB39
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
31/45
P[aweł] Kawalec, M. Czech, T. Faluta.
Budget impact of dopamine agonists in Poland.
Value in Health
2007 : Vol. 10, nr 6, s. A380, abstr PND3
ISPOR Tenth Annual European Congress, Dublin, Ireland, 20-23 October 2007.
SZZ
SIF
32/45
P[aweł] Kawalec, M[onika] Szkultecka-Debek, M. Russell.
CMA of mycophenolan mofetil (MMF; CellCept) or tacrolimus (TAC; Prograf) in kidney transplant immunosuppressive therapy schemes from public payer's perspective in Poland.
Value in Health
2007 : Vol. 10, nr 6, s. A315, abstr. PUK8
ISPOR Tenth Annual European Congress, Dublin, Ireland, 20-23 October 2007.
SZZ
SIF
33/45
P[aweł] Kawalec, C. Glogowski, M. Cel.
Cost-effectiveness of Augmentin ES for the treatment of paediatric acute otitis media (AOM) in Poland.
Value in Health
2007 : Vol. 10, nr 6, s. A440, abstr. PIN15
ISPOR Tenth Annual European Congress, Dublin, Ireland, 20-23 October 2007.
SZZ
SIF
34/45
P[aweł] Kawalec, M. Cel, C. Glogowski.
Cost-effectiveness of Augmentin ES vs azithromycin for the treatment of paediatric acute otitis media (AOM) in Poland.
Value in Health
2007 : Vol. 10, nr 6, s. A440, abstr. PIN16
ISPOR Tenth Annual European Congress, Dublin, Ireland, 20-23 October 2007.
SZZ
SIF
35/45
A[gnieszka] Skowron.
Impact of changes in reimbursement system on the budget from the payer's and patient's perspective.
Value in Health
2007 : Vol. 10, nr 6, s. A409-A410, abstr. PCV15
ISPOR Tenth Annual European Congress, Dublin, Ireland, 20-23 October 2007.
SZZ
SIF
36/45
A[gnieszka] Skowron, S[ebastian] Polak, J[erzy] Brandys.
A cost minimisation analysis of navelbine-cisplatin versus gemcitabine-cisplatin in advanced non-small cell lung cancer in Poland.
Value in Health
2006 : Vol. 9, nr 6, s. A285, abstr. PCN31
ISPOR Ninth Annual European Congress, Copenhagen, Denmark, 28-31 October, 2006.
SZZ
SIF
37/45
S[ebastian] Polak, A[gnieszka] Skowron, A[leksander] Mendyk, J[erzy] Brandys.
Assesment of the computational intelligence based models usefulness for pharmacoeconomics needs.
Value in Health
2006 : Vol. 9, nr 6, s. A294, abstr. PCN60.
ISPOR Ninth Annual European Congress, Copenhagen, Denmark, 28-31 October, 2006.
SZZ
SIF
Adres url:
38/45
P[aweł] Kawalec, C. Glogowski, A. Krzyzanowska.
Burden of cervical cancer in Poland.
Value in Health
2006 : Vol. 9, nr 6, s. A286, abstr. PCN36
ISPOR Ninth Annual European Congress, Copenhagen, Denmark, 28-31 October, 2006.
SZZ
SIF
39/45
P[aweł] Kawalec, E. Borek.
Clinical effectiveness of Betaloc ZOC compared to metoprolol tartrate or carvedilol in hypertension treatment.
Value in Health
2006 : Vol. 9, nr 6, s. A340, abstr. PCV 11
ISPOR Ninth Annual European Congress, Copenhagen, Denmark, 28-31 October, 2006.
SZZ
SIF
40/45
P[aweł] Kawalec, J. Lis.
Cost minimalization analysis of average acute hospital infections treatment with targocid (teicoplanin) or vancomycine from service-provider perspective in Poland.
Value in Health
2006 : Vol. 9, nr 6, s. A302, abstr. PIN 12
ISPOR Ninth Annual European Congress, Copenhagen, Denmark, 28-31 October, 2006.
SZZ
SIF
41/45
P[aweł] Kawalec, E. Borek.
Cost-effectiveness of Betaloc compared to carvedilol in cardiac insufficiency and arterial hypertension treatment in Poland.
Value in Health
2006 : Vol. 9, nr 6, s. A345, abstr. PCV27
ISPOR Ninth Annual European Congress, Copenhagen, Denmark, 28-31 October, 2006.
SZZ
SIF
42/45
A[gnieszka] Skowron, J. Pazdziora, J[erzy] Brandys.
Impact of changes in the financing of the health services on costs structure on the example of chemotherapy pf advanced ovarian cancer.
Value in Health
2006 : Vol. 9, nr 6, s. A277, abstr. PCN7
ISPOR Ninth Annual European Congress, Copenhagen, Denmark, 28-31 October, 2006.
SZZ
SIF
Adres url:
43/45
P[aweł] Kawalec, J. Lis, J. Gierczynski.
Cost of community acquired pneumonia (CAP) treatment with Ketek (telithromycin) vs clarithromycin from public payer perspective in Poland.
Value in Health
2005 : Vol. 8, nr 6, s. A214, abstr. PRS9
ISPOR Eighth Annual European Congress, Florence, Italy, November 6-8, 2005.
SZZ
SIF
44/45
P[aweł] Kawalec, C. Glogowski, A. Krzyzanowska.
Cost of kalium supplementaion with Kalipoz prolongatum or Kaldyum from payer perspective in Poland.
Value in Health
2004 : Vol. 7, nr 6, s. 731, abstr. PBR I
ISPOR Seventh Annual European Congress, Hamburg, Germany, 24-26 October, 2004.
SZZ
SIF
45/45
S[ebastian] Polak, A[gnieszka] Skowron, J[erzy] Brandys, A[leksander] Mendyk.
Modeling effect in pharmacoeconomics analysis using artificial neural networks.
Value in Health
2004 : Vol. 7, nr 6, s. 683-684, abstr.
ISPOR Seventh Annual European Congress, Hamburg, Germany, 24-26 October, 2004.
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ